Jyong Biotech Ltd. Ordinary Shares (MENS) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MENS Revenue Growth
MENS Revenue Analysis (2020–2024)
As of May 8, 2026, Jyong Biotech Ltd. Ordinary Shares (MENS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2024) recorded $0 in revenue.
Looking at the longer-term picture, MENS's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including AEYE (+14.5% YoY), NUVB (+1205.5% YoY), and HALO (+37.6% YoY). Compare MENS vs AEYE →
MENS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MENSCurrent | $0 | - | - | - | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 OCGN | $4M | +8.8% | +152.5% | -1425.7% |
MENS Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-120,000 | - | $-2,056,000 | - |
| 2023 | $0 | - | $-127,000 | - | $-2,797,000 | - |
| 2022 | $0 | - | $-122,000 | - | $-2,829,000 | - |
| 2021 | $0 | - | $-121,000 | - | $-2,404,000 | - |
| 2020 | $0 | - | $0 | - | $-2,446,000 | - |
See MENS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MENS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MENS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMENS — Frequently Asked Questions
Quick answers to the most common questions about buying MENS stock.
Is MENS's revenue growth accelerating or slowing?
MENS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MENS's long-term revenue growth rate?
Jyong Biotech Ltd. Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MENS's revenue distributed by segment?
MENS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.